Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Products under Development by Stage of Development | 8 | 1 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Products under Development by Therapy Area | 9 | 1 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Products under Development by Indication | 10 | 1 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Products under Development by Companies | 13 | 2 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Products under Development by Universities/Institutes | 15 | 2 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 2 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Companies Involved in Therapeutics Development | 22 | 2 |
| Rigontec GmbH | 22 | 1 |
| Spring Bank Pharmaceuticals, Inc. | 23 | 1 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Drug Profiles | 24 | 11 |
| ImOl-100 Drug Profile | 24 | 1 |
| Oligonucleotide to Activate RIG-1 for Influenza and Viral Infections Drug Profile | 25 | 1 |
| SB-44 Drug Profile | 26 | 1 |
| SB-9200 Drug Profile | 27 | 5 |
| SB-9400 Drug Profile | 32 | 1 |
| SB-9941 Drug Profile | 33 | 1 |
| SB-9946 Drug Profile | 34 | 1 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Dormant Projects | 35 | 1 |
| Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) Featured News &Press Releases | 36 | 14 |
| Jun 22, 2016: Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B | 36 | 1 |
| Apr 21, 2016: Spring Bank Pharmaceuticals Presents Data on Immunomodulatory Agent SB 9200 at the 29th International Conference on Antiviral Research | 37 | 2 |
| Apr 14, 2016: Spring Bank Pharmaceuticals Presents Data on Immunomodulatory Agent SB 9200 at the 2016 European Association for the Study of the Liver Annual Meeting | 39 | 1 |
| Mar 31, 2016: Spring Bank Pharmaceuticals to Present Results from Preclinical Studies of SB 9200 in HBV and HCV at EASL 2016 | 40 | 1 |
| Feb 23, 2016: Spring Bank Pharmaceuticals Announces Grant of European Patent for SMNH Analogs Including SB 9200 | 41 | 1 |
| Dec 08, 2015: Spring Bank Pharmaceuticals Reports Preclinical Data on the Use of SB 9200 with Entecavir in the Woodchuck Model of HBV | 41 | 1 |
| Nov 16, 2015: Spring Bank Pharmaceuticals Presents Positive Phase 1 Data on SB 9200 at the 2015 American Association for the Study of Liver Diseases Annual Meeting | 42 | 1 |
| Oct 13, 2015: Spring Bank Pharmaceuticals Announces Presentation of Results from Phase I Clinical Trial Supporting the Novel Mechanism of Action of SB 9200 in Patients with Hepatitis C at The Liver Meeting | 43 | 1 |
| Apr 27, 2015: Spring Bank Pharmaceuticals Presents Preclinical and Clinical Data on Immunomodulatory Agent SB 9200 at the 2015 Annual Meeting of the European Association for the Study of the Liver | 43 | 2 |
| Apr 13, 2015: Spring Bank Pharmaceuticals to Present HBV and HCV Results with SB 9200 at EASL 2015 | 45 | 1 |
| Mar 12, 2015: Spring Bank Pharmaceuticals to Present Novel Approach to Hepatitis B Treatment at the 2015 AASLD and Industry Colloquium | 46 | 1 |
| Sep 18, 2014: Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens | 47 | 1 |
| Jun 23, 2014: Spring Bank Pharmaceuticals Presents at the Nucleic Acid Summit 2014 | 48 | 1 |
| May 12, 2014: Spring Bank Pharmaceuticals Announces Oral and Poster Presentations At The 27th International Conference On Antiviral Research | 48 | 1 |
| Nov 26, 2013: Spring Bank Pharmaceuticals Commences Multiple Ascending Dose (MAD) Stage of Phase 1 clinical in HCV Patients | 49 | 1 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |
